Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 25 of 55

TitleReference numberPublishedLast updated
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabineTA440
Ixekizumab for treating moderate to severe plaque psoriasisTA442
Obeticholic acid for treating primary biliary cholangitisTA443
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal)TA240
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)TA438
Elotuzumab for previously treated multiple myeloma (terminated appraisal)TA434
Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal)TA435
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)TA436
Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal)TA437
Ustekinumab for treating active psoriatic arthritisTA340
Ustekinumab for treating moderate to severe plaque psoriasisTA180
Everolimus for advanced renal cell carcinoma after previous treatmentTA432
Apremilast for treating active psoriatic arthritisTA433
Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutationTA429
Sofosbuvir–velpatasvir for treating chronic hepatitis CTA430
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomibTA427
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimensTA423
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancerTA424
Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemiaTA425
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemiaTA426
Everolimus with exemestane for treating advanced breast cancer after endocrine therapyTA421
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancerTA422
Ticagrelor for preventing atherothrombotic events after myocardial infarctionTA420
Nivolumab for previously treated advanced renal cell carcinomaTA417
Dapagliflozin in triple therapy for treating type 2 diabetesTA418

Results per page

  1. 10
  2. 25
  3. 50
  4. All